Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

On the eve of the expected unveiling next week of the federal Conservatives' long-waited anti-drug strategy, a significant new study has endorsed the benefits of Vancouver's controversial safe-injection site for heroin addicts, a pilot project many fear Ottawa will end.

The study, published today in the London-based medical journal Addiction, found that use of the city's supervised injection facility known as Insite increased the rate of addicts entering detox by 30 per cent.

As well, the study determined users of North America's only safe-injection site were more likely to reduce their heroin intake and pursue formal treatment programs such as methadone once they left detox.

Story continues below advertisement

The dramatic findings appear to echo precisely what the ultimate arbiter of the facility's fate, federal Health Minister Tony Clement, has said Insite needs to demonstrate to prove its worth: lower drug use and success in fighting addiction.

They also fly in the face of an earlier RCMP report critical of the site, asserting there is "considerable evidence" that allowing addicts to shoot up safely increases the use of illegal drugs.

Despite the study, however, Insite backers continue to worrythat the distaste of many Conservatives for harm-reduction programs, which treat drug addiction as a health problem rather than a criminal matter, will result in the centre's demise by the end of the year.

They point to numerous previous scientific studies in medical publications such as the New England Journal of Medicine and The Lancet, all of which found a positive impact on drug users and the surrounding neighbourhood since Insite opened more than three years ago.

Yet Mr. Clement has called for more research before making a decision on the facility's future.

"The government has seemed intent on ignoring scientific evidence to pursue an ideological agenda at the expense of lives in the Downtown Eastside," said Dr. Julio Montaner, one of the study's authors and director of the B.C. Centre for Excellence in HIV/AIDS.

"It is time for the federal government to accept the evidence and move the debate to a higher level."

Story continues below advertisement

Underscoring widespread skepticism among many researchers over the government's alleged anti-harm-reduction agenda is a decision by five leading scientists to boycott bidding for Health Canada contracts to conduct further research into Insite's operation.

In an open letter to senior Health Canada policy analyst Tracey Donaldson, the group said the five-month time frame is too short, compensation is insufficient and successful bidders must agree to keep mum over their research for six months.

"In no way is that acceptable to any academic," one of the scientists, Benedikt Fischer of the University of Victoria, said yesterday. "And how can anyone produce anything meaningful in such a short time that goes beyond what has already been done by other researchers? There are already 40 to The Addiction study based its findings on interviews and database searches involving more than 1,000 Insite users. Researchers compared their activity in the year before visiting Insite and the year following their first use of the facility.

A complicated mathematical adjustment taking other factors into consideration produced a final conclusion that the rate of addicts entering detoxification rose 30 per cent among those using the injection facility.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies